ecrin-mdr-crcClinical2009Second-Line Treatment for Metastatic Colorectal CancerColorectal Cancer (CRC)Colorectal NeoplasmsMetastatic colorectal cancerMetastatic Colorectal CancerSecond-line Treatment For Metastatic Colorectal CancerColorectal Cancer (crc)Colorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2068498ArgentinaUnited StatesItalyFrance10IrinotecanCalciumIrinotecan Hydrochloride, trihydrateLevoleucovorinLeucovorinNeofolin5-FU HexalPharmaceutical SolutionsCT-322FluorouracilBevacizumabECRIN MDRCompletedfalsePh II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal CancerThe purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer2009-10-152068498NCT008510452008-006561-89